Literature DB >> 16864667

Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? PET and MR imaging study.

Paul Knaapen1, Marco J W Götte, Walter J Paulus, Jaco J M Zwanenburg, Pieter A Dijkmans, Ronald Boellaard, J Tim Marcus, Jos W R Twisk, Cees A Visser, Albert C van Rossum, Adriaan A Lammertsma, Frans C Visser.   

Abstract

PURPOSE: To prospectively evaluate, by using positron emission tomography (PET) and magnetic resonance (MR) imaging, the interrelationships between regional myocardial fibrosis, perfusion, and contractile function in patients with idiopathic dilated cardiomyopathy (DCM).
MATERIALS AND METHODS: The study protocol was approved by the hospital ethics committee, and all subjects gave written informed consent. Sixteen patients with idiopathic DCM (mean age, 54 years +/- 11 [standard deviation]; nine men) and six healthy control subjects (mean age, 28 years +/- 2; five men) were examined with PET and MR tissue tagging. Oxygen 15-labeled water and carbon monoxide were used as tracers at PET to assess myocardial blood flow (MBF) and the perfusable tissue index (PTI), which is inversely related to fibrosis. MBF was determined at rest and during pharmacologically induced hyperemia. Maximum circumferential shortening (E(cc)) was determined with MR tissue tagging. Student t tests were performed for comparison of data sets, and linear regression was used to investigate the association between parameters.
RESULTS: Mean global hyperemic MBF (2.23 mL/min/mL +/- 0.73), E(cc) (-10.5% +/- 2.9), and PTI (0.95 +/- 0.10) were lower in the patients with DCM than in the control subjects (4.33 mL/min/mL +/- 0.85, -17.4% +/- 0.6, and 1.09 +/- 0.12, respectively; P < .05 for all). In the patients with DCM, regional PTI was related to E(cc) (r = -0.21, P = .009) but not to resting or hyperemic MBF. Furthermore, regional E(cc) was correlated to both resting (r = -0.28, P = .004) and hyperemic MBF (r = -0.29, P < .001). In addition, the ratio of left ventricular end-diastolic volume to mass, as a reflection of wall stress, was related to global hyperemic MBF (r = -0.52, P = .047) and to global E(cc) (r = 0.69, P = .003).
CONCLUSION: In idiopathic DCM, the extent of myocardial fibrosis is related to the impairment in contractile function, whereas fibrosis and perfusion do not seem to be interrelated. The degree of impairment of hyperemic myocardial perfusion is related to contractility and end-diastolic wall stress. RSNA, 2006

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864667     DOI: 10.1148/radiol.2402051038

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

Review 1.  Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective.

Authors:  Antonis Kalemis; Bénédicte M A Delattre; Susanne Heinzer
Journal:  MAGMA       Date:  2012-08-07       Impact factor: 2.310

2.  Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy.

Authors:  Michael Jerosch-Herold; David C Sheridan; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Diana Dutton; Rami Alharethi; Duanxiang Li; Ray E Hershberger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

3.  Reduced regional myocardial perfusion reserve is associated with impaired contractile performance in idiopathic dilated cardiomyopathy.

Authors:  R A Tio; R H J A Slart; R A de Boer; P A van der Vleuten; R M de Jong; L M van Wijk; T Willems; D D Lubbers; A A Voors; D J van Veldhuisen
Journal:  Neth Heart J       Date:  2009-12       Impact factor: 2.380

4.  Sirtuin 6 deficiency transcriptionally up-regulates TGF-β signaling and induces fibrosis in mice.

Authors:  Sangeeta Maity; Jaseer Muhamed; Mohsen Sarikhani; Shweta Kumar; Faiz Ahamed; Kondapalli Mrudula Spurthi; Venkatraman Ravi; Aditi Jain; Danish Khan; Bangalore Prabhashankar Arathi; Perumal Arumugam Desingu; Nagalingam R Sundaresan
Journal:  J Biol Chem       Date:  2019-11-19       Impact factor: 5.157

5.  Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.

Authors:  Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

6.  Early diastolic strain rate predicts response to heart failure therapy in patients with dilated cardiomyopathy.

Authors:  Björn Goebel; Kristina H Haugaa; Kathleen Meyer; Sylvia Otto; Christian Jung; Alexander Lauten; Hans R Figulla; Thor Edvardsen; Tudor C Poerner
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-30       Impact factor: 2.357

7.  Evaluation of Modified Look-Locker Inversion Recovery and Arrhythmia-Insensitive Rapid Cardiac T1 Mapping Pulse Sequences in Cardiomyopathy Patients.

Authors:  Sean Robison; KyungPyo Hong; Daniel Kim; Rachel Lloyd; Jay Ramchand; Emma Hornsey; Piyush Srivastava; Gerard Smith; Leighton Kearney; Ruth Lim
Journal:  J Comput Assist Tomogr       Date:  2018 Sep/Oct       Impact factor: 1.826

Review 8.  Fibrosis in hypertrophic cardiomyopathy: role of novel echo techniques and multi-modality imaging assessment.

Authors:  Efstathios D Pagourelias; Georgios M Alexandridis; Vassilios P Vassilikos
Journal:  Heart Fail Rev       Date:  2021-05-15       Impact factor: 4.214

9.  The emerging role of magnetic resonance imaging and multidetector computed tomography in the diagnosis of dilated cardiomyopathy.

Authors:  Massimo Slavich; Anca Florian; Jan Bogaert
Journal:  Insights Imaging       Date:  2011-05-19

Review 10.  Fibrosis imaging: Current concepts and future directions.

Authors:  Maike Baues; Anshuman Dasgupta; Josef Ehling; Jai Prakash; Peter Boor; Frank Tacke; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2017-11-20       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.